Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale

Johnson & Johnson maintained a substantial revenue lead over Bristol Myers Squibb in every quarter from Q3 2024 through Q2 2026, ending at $25.3 billion versus $13.0 billion. Both companies showed gradual top-line growth, but J&J expanded from a materially larger base and slightly outpaced BMY's growth rate over the period. J&J's $33.79 billion 2025 medtech business, recent $1 billion Firefly Bio acquisition, and OTTAVA robotic surgery authorization provide additional potential growth drivers absent from BMY's pure-play biopharma model.

Analysis

The relevant relative-value issue is not revenue scale but durability of post-2026 earnings power. JNJ has a diversified earnings engine: procedure-volume-linked MedTech can offset pharmaceutical pricing and patent-cycle pressure, while its installed-base strategy in robotics could create high-margin recurring instruments and service revenue. The near-term risk is that robotics and ADC acquisitions dilute returns before utilization ramps; MedTech growth needs to reaccelerate above low-single-digits for the segment to earn a valuation premium.

BMY remains a more concentrated patent-cliff and execution story. Its manufacturing expansion and pipeline advances matter only if they produce enough replacement revenue to close the gap left by legacy-product erosion; capacity spending ahead of proven demand would pressure free cash flow and reinforce its discounted multiple. In the next 1-3 months, the market will focus less on reported sales and more on Eliquis durability, the pace of legacy erosion, and whether new-launch guidance is raised.

Consensus likely overweights JNJ's defensive quality while underweighting its capital-allocation hurdle: incremental MedTech M&A and robotics commercialization must generate returns above the cost of capital, not merely add revenue. Conversely, BMY can rerate sharply from a depressed base if management demonstrates that new-product growth is genuinely outpacing loss-of-exclusivity declines, but this requires evidence across multiple quarters rather than a single regulatory milestone.

Key Decisions for Investors

• Maintain a 6-12 month long JNJ / short BMY pair, sized modestly: JNJ offers diversification and potential MedTech multiple support, while BMY remains exposed to pipeline-replacement proof. Reassess if BMY's new-product revenue trajectory exceeds legacy erosion for two consecutive earnings reports or JNJ MedTech organic growth remains below 3%.
• Ahead of the next earnings cycle, own JNJ only on post-results weakness rather than chase: add if guidance confirms accelerating MedTech utilization and no material margin dilution from platform acquisitions. A guidance cut tied to procedure softness or acquisition-related costs falsifies the near-term catalyst.
• Do not treat BMY's manufacturing investment as a standalone long catalyst. Set an alert for explicit multi-year new-launch sales guidance, launch uptake data, and capex/free-cash-flow conversion; absent those data, BMY is a watch item rather than a directional recommendation.
• For sector exposure, prefer JNJ over XLV when seeking healthcare defensiveness over the next 3-6 months: its non-pharma revenue stream should reduce earnings sensitivity to drug-pricing and exclusivity headlines. Exit the relative overweight if MedTech growth decelerates materially while large-pharma peers sustain higher organic growth.